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S346 Poster Session IIHowever, its costs and economic burden have not been well
described. Umbilical cord blood (UCB) transplantation is an
alternative donor source that has been reported to have lower
risks of CGVHD compared to matched related donor (MRD)
and unrelated donor transplantation. We conducted a single cen-
ter retrospective analysis to describe resource utilization associ-
ated with CGVHD. We also compared resources used by
recipients of UCB and MRD HCT. We assembled a cohort of
adult patients ($ 18 years) who received an allogeneic HCT at
our center from 2005-2007, had survived for at least 100 days
post-transplant and had a diagnosis of CGVHD. From the 83 pa-
tients (MRD 42. UCB 41) who met our criteria, we limited our
study to patients who had received all their care at our center
through 2 years post-HCT, relapse or death, which ever occurred
earlier. Our final cohort included 51 patients (MRD 29, UCB 22).
For both donor sources, included and excluded patients had com-
parable NIH severity, type and onset of CGVHD. For compari-
son purposes, we randomly selected a group of 45 controls who
met the same criteria as cases but had no CGVHD. Controls
were matched to cases by donor source and duration of followup
after HCT. For MRD and UCB recipients, median time to onset
of CGVHD was 175 and 144 days (P 5 0.73) and 55% and 59%
presented with overlap syndrome (P 5 0.78), respectively. Over-
all, 7%, 72% & 21% MRD and 27%, 65% & 5% UCB had
NIH graded mild, moderate and severe CGVHD (P 5 0.06).
Table 1 shows utilization of various resources among patients
with CGVHD and controls. There were similar patterns of re-
source utilization with respect to number of outpatient visits, hos-
pitalizations, and duration of hospital stay among UCB and MRD
recipients with CGVHD. However, a larger number of UCB re-
cipients with CGVHD were excluded because of receipt of care
elsewhere. Patients with chronic GVHD utilize extensive health
system resources. More research is needed to better understand
the costs of CGVHD to patients, centers and the health care
system and to determine if the lower incidence and severity of
CGVHD with UCB leads to long-term resource savings com-
pared to other graft sources.537
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Shwachman Diamond Syndrome (SDS) is a rare autosomal reces-
sive disorder with a varied clinical presentation of developmental,
metabolic and hematopoetic defects. Bone marrow transplantation
(BMT) is an accepted therapy to correct the potentially fatal compli-
cations of bone marrow failure, granulocytopenia and thrombocyto-
penia that are associated with SDS.
The subject of this report is a 10 year old girl diagnosed with SDS.
After a prolonged history of life-threatening infections and throm-
bocytopenia, BMT was pursued. Following myeloablative therapy,
the patient received a BMT from a 9/10 matched unrelated donor
(MUD). Complete engraftment was noted at two weeks by short tan-
dem repeat (STR) analysis of the mononuclear cells (MNC) and
granulocytes. The clinical course over the next year was complicated
by multi-organ graft versus host disease (GVHD) requiring liver
transplantation from a living related donor.Within 6months the pa-
tient was re-hospitalized with recurrent GVHD. STR analysis iden-
tified the presence of MNC derived from the solid organ transplant.
Regular monitoring of the engraftment by STR revealed that the
solid organ transplant-derived cells rapidly and selectively reconsti-
tuted the T cell compartment of the peripheral blood. Surprisingly,
the granulocyte and B cells were derived from the HSC donor. Fol-
lowing a complicated course of bone marrow aplasia, thrombocyto-
penia, sepsis and renal insufficiency the patient succumbed to
GVHD.
GVHD following solid organ transplantation is relatively uncom-
mon; however, the effects can be devastating. Here we present a casewhere passenger T cells from a solid organ transplant elicited
GVHD. These results demonstrate that the solid organ-derived T
cells were able to mount an effective immune response against the
patient and the HSC donor resulting in renal failure and bone
marrow aplasia, respectively. These results highlight the necessity
of determining compatibility between all cell and tissue types in-
volved in complex transplantation procedures.538
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Graft versus host disease (GVHD) is a major cause of morbidity
and mortality after allogeneic hematopoietic cell transplant
(HCT). Extracorporeal photopheresis (ECP) has been used success-
fully in the treatment of steroid refractory GVHD. Our center first
used ECP for GVHD in 1999. Our protocol for treatment of cuta-
neous GVHD is ECP two days per week every other week for three
months then reevaluate. If GVHD is improving, the frequency of
treatment would be reduced to two days per month. For visceral
GVHD, ECP treatment would be given three days per week every
other week for three months and then reassess and taper as above.
We currently use vortex ports (AngioDynamics, Latham, NY) for
long term access in our HCT patients and we hypothesize that it is
possible to perform ECP using vortex ports in patients with steroid
refractory GVHD and that the use of the port instead of external
catheters or venopuncture will improve quality of life for these
patients.
Patients who received at least one ECP treatment for treatment of
steroid refractory GVHD at our center between 1/1/07 and 9/30/10
were included (n5 47). During that time our center performed 1632
ECP procedures for treatment of GVHD including 552 procedures
after vortex port placement in 19 patients. Fifteen patients completed
100% of their ECP procedures with the vortex port after it was
placed. These patients had a total of 400 procedures with a range
of 6-51 procedures and a mean of 26.7 per patient. Four patients
had some of their procedures done with the port but required an-
other access method for 19 procedures. These patients had a total
of 133 procedures with a range of 27-36 and a mean 33.25 per pa-
tient. Of the patients that did not use the vortex port 100% of the
time, one had an uncomplicated line infection, one preferred IV ac-
cess to port use, one had anatomic issues with port placement, and
one had access to the port impaired by scleroderma. Overall, 97%
(533/552) of ECP procedures performed in patients with a vortex
port were completed using the port. Therefore, we conclude that
the use of the vortex port for ECP patients with steroid refractory
GVHD is feasible. Future studies are needed to evaluate infection
rate, bleeding risk, and quality of life in these patients compared
with those receiving ECP with external catheters or venopuncture
particularly in patients with sclerodermatous cutaneous GVHD.539
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Acute graft-versus-host disease (aGVHD) has remained a signifi-
cant cause of non-relapse mortality after allogeneic hematopoietic
cell transplantation (HCT). The conditions favoring the develop-
ment of aGVHD are thought to occur in the earliest phases of
